- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
July 13 Reception Will Celebrate Major Milestones at One-Year Mark
NanoBioNexus, Inc., a non-profit forum for business, networking and partnering opportunities in nanobiotechnology, celebrates its first anniversary and announces the continuing support of founding sponsor, Morrison and Foerster LLP. The significant milestones reached by the organization have also attracted new support and sponsorship including Duke Scientific Corporation; Buchanan Ingersoll LLP including attorneys from Burns Doane Swecker & Mathis; Veracast Communications; Rudolph and Sletten; Summit Financial Group; BayCreative; Biotech Vendor Services, Inc.; and ScienceMedia.
“I’m very pleased with the milestones we’ve achieved as an organization in our first year of operation,” commented Adriana Vela, Founder and Chair of NanoBioNexus (NBN). “Our programs are well attended and our partnership with the business community continues to expand. We were honored to receive an invitation to participate in a grant application from the National Cancer Institute (NCI), and we’re currently in discussions with several major scientific publishers that are interested in acquiring the NanoBioNexus News content for ongoing columns.”
The industry supports and continues to validate the unique value NBN brings to the local life science community as well as their national and international nanobiotech constituency. NBN’s expertise led to an invitation to join the UCSD Cancer Center, The Burnham Institute, UC Riverside, UC Santa Barbara and others in a $20.5 million grant application for the creation of a Cancer Center of Nanotechnology Excellence (CCNE) in San Diego. The NCI made a significant commitment to nanotechnology research for cancer and set aside a total of $144.3 million for the formation of five CCNE’s nationwide. NBN will head the educational component of this grant.
“Before NanoBioNexus formed in San Diego, there was a great deal of interest in nanotech but no central point of knowledge or contact,” commented Tyler Orion, CEO of San Diego’s Regional Technology Alliance. “NBN mobilized thought leaders in nanotechnology and quickly became a central resource for knowledge and networking.”
The NBN organization continues to grow internally and has been fortified by a newly named Board of Directors: Aileen Alvarado-Swaisgood, Ph.D., MBA, Founder, Molecular Alliance; James T. Clements, MBA, Principal and VP Business Development, NanoSciences, Inc.; Alan S. Paau, PhD, Assistant Vice Chancellor, UCSD Tech Transfer Office; Philip Reilly, JD, PhD, Director of Legal Affairs, Macusight, Inc.; and Adriana Vela, Founder & Chair, NanoBioNexus, Inc.
A special “NanoBioNexus Anniversary and Reception Gala” celebrating the milestones of the past year will be held July 13 at the Salk Institute in La Jolla from 5:30 p.m. to 8 p.m. The event provides an excellent opportunity for attendees to spend quality time networking with business and scientific leaders.
Register for the reception at www.acteva.com/go/nanobionexus
NanoBioNexus is the only San Diego organization exclusively dedicated to nanobiotechnology. It is a non-profit, volunteer-managed organization that showcases applications of nanotechnology in the Life Sciences. The NanoBioNexus mission is to facilitate economic development and provide community service. The organization offers excellent learning opportunities via its publications and through networking in an open and congenial environment. NanoBioNexus serves as a catalyst for forming relationships and exchanging ideas by sponsoring acclaimed, ongoing forums that bring together scientists, entrepreneurs, technology experts and venture capitalists. NanoBioNexus enables those in the Southern California area and beyond to keep up-to-date on the nanobio business environment. The group's target audience is business and legal professionals, venture capitalists, entrepreneurs, academia, industrial scientists, and members of the general public with an interest in nanobiotechnology.
For more information, please visit www.nanobionexus.orgContact:
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016
Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016
Quantum obstacle course changes material from superconductor to insulator December 1st, 2016
Throwing new light on printed organic solar cells December 1st, 2016